Skip to content
Delayed ~15 min

CNTX CONTEXT THERAPEUTICS INC

Health Care · Russell 2000

Next earnings: not announced yet

What 14 analyst firms say about CONTEXT THERAPEUTICS INC: their latest ratings, price targets and how far the stock is from them. How it works

0.19 USD+0.01 (+2.98%) today
Price as of 6 Nov 16:00 ET

Analyst window: Latest analyst report within last 1 year

Analyst view · last 1Y

+2,639.0%to the avg target 5.30 USD+5.11 USD
Buy 12 · Hold 1 · Sell 1

14 rated views · 15 analyst/firm records · 14 firms

Latest report6 Aug 2026avg report date 4 Jun
Target rangePrice is below every target

Radar score

  • Russell 2000 · Top Picks · 6MNot scored · Price below 5 USD
  • Russell 2000 · Safest consensus · 6MNot scored · Price below 5 USD

Recent analyst activity · last 90 days

Our tracked history has 2 reports on CNTX from 2 analyst firms in the last 90 days (14 firms in the past year).

Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.

FirmAnalystLatest ratingReport dateLatest target (USD)
Cantor FitzgeraldLi WatsekBuy15 Jun 2026—
CitigroupUnnamed analystBuy6 Aug 2026—
Citizens JMPSilvan C TuerkcanBuy1 Jul 20263.00 USD
D Boral CapitalJason KolbertBuy24 Mar 20269.00 USD
D Boral CapitalPatrick MccannBuy21 May 20269.00 USD
GuggenheimPaul JengBuy24 Mar 20265.00 USD
H.C. WainwrightEmily BodnarBuy6 Aug 20265.00 USD
JonestradingSoumit RoyBuy9 Jun 20262.00 USD
Lifesci CapitalCharles ZhuHold6 Aug 20266.00 USD
Maxim GroupJason McCarthyBuy16 Jun 20264.00 USD
Piper SandlerBiren AminBuy6 Aug 20267.00 USD · 24 Mar 2026
Rodman & RenshawMichael G KingBuy5 Aug 20263.00 USD
Weiss RatingsUnnamed analyst—15 Oct 2026—
William BlairMatt PhippsBuy6 Aug 2026—
Data feed RESEARCHResearch TeamSell12 Oct 2026—

Partial coverage · checked 6 Nov (6 Nov 2026, 03:44 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.